Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Acta Neurologica Belgica
Published in: Acta Neurologica Belgica 2/2018

01-06-2018 | Consensus paper and Guideline

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis

Authors: Guy Laureys, Barbara Willekens, Ludo Vanopdenbosch, Olivier Deryck, Dominik Selleslag, Miguel D’Haeseleer, Ann De Becker, Bénédicte Dubois, Daan Dierickx, Gaetano Perrotta, Virginie De Wilde, Vincent van Pesch, Nicole Straetmans, Dominique Dive, Yves Beguin, Bart Van Wijmeersch, Koen Theunissen, Tessa Kerre, Ann Van de Velde

Published in: Acta Neurologica Belgica | Issue 2/2018

Login to get access

Abstract

Multiple sclerosis is considered to be an immune mediated inflammatory disorder of the central nervous system. It mainly affects young, socioeconomic active patients. Although our armamentarium for this disease has significantly evolved in recent years some patients remain refractory to conventional therapies. In these cases, autologous hematopoietic stem cell transplantation can be considered as a therapeutic option. Decreasing morbidity, mortality, and increasing patient awareness have led to rising inquiry by our patients about this treatment option. With the aim of a standardized protocol and data registration, a Belgian working party on stem cell therapy in multiple sclerosis was established. In this paper, we report the consensus protocol of this working party on autologous hematopoietic stem cell transplantation in multiple sclerosis.
Appendix
Available only for authorised users
Literature
1.
Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vecsei L et al (2006) The epidemiology of multiple sclerosis in Europe. Eur J Neurol 13(7):700–722CrossRefPubMed
2.
van Ooteghem P, D’Hooghe MB, Vlietinck R, Carton H (1994) Prevalence of multiple sclerosis in Flanders, Belgium. Neuroepidemiology 13(5):220–225CrossRefPubMed
3.
Dendrou CA, Fugger L, Friese MA (2015) Immunopathology of multiple sclerosis. Nat Rev Immunol 15(9):545–558CrossRefPubMed
4.
Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46(4):907–911CrossRefPubMed
5.
Gholipour T, Healy B, Baruch NF, Weiner HL, Chitnis T (2011) Demographic and clinical characteristics of malignant multiple sclerosis. Neurology 76(23):1996–2001CrossRefPubMed
6.
Menon S, Shirani A, Zhao Y, Oger J, Traboulsee A, Freedman MS et al (2013) Characterising aggressive multiple sclerosis. J Neurol Neurosurg Psychiatry 84(11):1192–1198CrossRefPubMed
7.
Comi G, Radaelli M, Soelberg Sorensen P (2017) Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet 389(10076):1347–1356CrossRefPubMed
8.
Fassas A, Passweg JR, Anagnostopoulos A, Kazis A, Kozak T, Havrdova E et al (2002) Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol 249(8):1088–1097CrossRefPubMed
9.
Mancardi GL, Sormani MP, Gualandi F, Saiz A, Carreras E, Merelli E et al (2015) Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology 84(10):981–988CrossRefPubMed
10.
Mancardi GL, Sormani MP, Di Gioia M, Vuolo L, Gualandi F, Amato MP et al (2012) Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. Mult Scler 18(6):835–842CrossRefPubMed
11.
Burt RK, Balabanov R, Han X, Sharrack B, Morgan A, Quigley K et al (2015) Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. JAMA 313(3):275–284CrossRefPubMed
12.
Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Steinmiller KC et al (2017) High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology 88(9):842–852CrossRefPubMedCentralPubMed
13.
Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M (2015) Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord 4(4):329–333CrossRefPubMed
14.
Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL (2015) Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol 72(2):152–158CrossRefPubMed
15.
Sormani MP, Muraro PA, Saccardi R, Mancardi G (2017) NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs. Mult Scler 23(2):201–204CrossRefPubMed
16.
Curro D, Mancardi G (2016) Autologous hematopoietic stem cell transplantation in multiple sclerosis: 20 years of experience. Neurol Sci 37(6):857–865CrossRefPubMed
17.
Freedman MS, Rush CA (2016) Severe, highly active, or aggressive multiple sclerosis. Continuum (Minneap Minn) 22(3):761–784
18.
Sormani MP, Muraro PA, Schiavetti I, Signori A, Laroni A, Saccardi R et al (2017) Autologous hematopoietic stem cell transplantation in multiple sclerosis: a meta-analysis. Neurology 88(22):2115–2122CrossRefPubMed
19.
Muraro PA, Martin R, Mancardi GL, Nicholas R, Sormani MP, Saccardi R (2017) Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat Rev Neurol 13(7):391–405CrossRefPubMed
20.
Snowden JA, Saccardi R, Allez M, Ardizzone S, Arnold R, Cervera R et al (2012) Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transpl 47(6):770–790CrossRef
21.
Meulenbergs T, Vermylen J, Schotsmans PT (2005) The current state of clinical ethics and healthcare ethics committees in Belgium. J Med Ethics 31(6):318–321CrossRefPubMedCentralPubMed
22.
Butzkueven H, Chapman J, Cristiano E, Grand’Maison F, Hoffmann M, Izquierdo G et al (2006) MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler 12(6):769–774CrossRefPubMed
23.
Rovira A, Wattjes MP, Tintore M, Tur C, Yousry TA, Sormani MP et al (2015) Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol 11(8):471–482CrossRefPubMed
24.
Olchowy C, Cebulski K, Lasecki M, Chaber R, Olchowy A, Kalwak K et al (2017) The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity—a systematic review. PLoS ONE 12(2):e0171704CrossRefPubMedCentralPubMed
25.
Filippi M, van Waesberghe JH, Horsfield MA, Bressi S, Gasperini C, Yousry TA et al (1997) Interscanner variation in brain MRI lesion load measurements in MS: implications for clinical trials. Neurology 49(2):371–377CrossRefPubMed
26.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302CrossRefPubMedCentralPubMed
27.
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ et al (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83(3):278–286CrossRefPubMedCentralPubMed
28.
Kappos L, Li D, Calabresi PA, O’Connor P, Bar-Or A, Barkhof F et al (2011) Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378(9805):1779–1787CrossRefPubMed
Metadata
Title
A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis
Authors
Guy Laureys
Barbara Willekens
Ludo Vanopdenbosch
Olivier Deryck
Dominik Selleslag
Miguel D’Haeseleer
Ann De Becker
Bénédicte Dubois
Daan Dierickx
Gaetano Perrotta
Virginie De Wilde
Vincent van Pesch
Nicole Straetmans
Dominique Dive
Yves Beguin
Bart Van Wijmeersch
Koen Theunissen
Tessa Kerre
Ann Van de Velde
Publication date
01-06-2018
Publisher
Springer International Publishing
Published in
Acta Neurologica Belgica / Issue 2/2018
Print ISSN: 0300-9009
Electronic ISSN: 2240-2993
DOI
https://doi.org/10.1007/s13760-018-0905-0

Other articles of this Issue 2/2018

Acta Neurologica Belgica 2/2018 Go to the issue

Review

Evaluation of hydrocephalus patients with 3D-SPACE technique using variant FA mode at 3T

Neuro-Images

Genetic Creutzfeldt–Jakob disease with an 8-year disease course

Original Article

Evaluation of diffusion tensor imaging changes and neurocognitive effects of asymptomatic vitamin B12 deficiency

Consensus paper and Guideline

Management of adverse renal events related to alemtuzumab treatment in multiple sclerosis: a Belgian consensus

Neuro-Images

An unusual cause of cavitating leukoencephalopathy: ethylmalonic encephalopathy

Letter to the Editor

Auto-immune hepatitis in a patient with multiple sclerosis treated with alemtuzumab